PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis

Science Translational Medicine

Volumn 6, Issue 265, 2014, Pages

  Coleman, M Teresa ^a   Chen, Ray Y ^b   Lee, Myungsun ^c   Lin, Philana Ling ^d   Dodd, Lori E ^b   Maiello, Pauline ^a   Via, Laura E ^b   Kim, Youngran ^c   Marriner, Gwendolyn ^b   Dartois, Veronique ^e   Scanga, Charles ^a   Janssen, Christopher ^f   Wang, Jing ^g   Klein, Edwin ^f   Cho, Sang Nae ^c,h   Barry, Clifton E ^b,i   Flynn, JoAnne L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c International Tuberculosis Research Center   (South Korea)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^e RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^h Yonsei University College of Medicine   (South Korea)

ⁱ UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 5847; LINEZOLID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; FLUORODEOXYGLUCOSE F 18; OXAZOLIDINONE DERIVATIVE; POSIZOLID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL LOAD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; LUNG TUBERCULOSIS; MACACA FASCICULARIS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); QUANTITATIVE ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; ALGORITHM; ANIMAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; LYMPH NODE; MACACA; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; STEM CELL; TREATMENT OUTCOME;

ACETAMIDES; ALGORITHMS; ANIMALS; ANTI-BACTERIAL AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; MACACA; MULTIMODAL IMAGING; OXAZOLIDINONES; POSITRON-EMISSION TOMOGRAPHY; STEM CELLS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84915818775     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3009500     Document Type: Article

References (32)

1. A. Zumla, A. George, V. Sharma, N. Herbert; Baroness Masham of Ilton, WHO's 2013 global report on tuberculosis: Successes, threats, and opportunities. Lancet 382, 1765-1767 (2013).
2. World Health Organization, in Treatment of Tuberculosis: Guidelines (WHO Press, Geneva, Switzerland, ed. 4, 2010).
3. K. A. Christian, K. Ijaz, S. F. Dowell, C. C. Chow, R. A. Chitale, J. S. Bresee, E. Mintz, M. A. Pallansch, S. Wassilak, E. McCray, R. R. Arthur, What we are watching - Five top global infectious disease threats, 2012: A perspective from CDC's Global Disease Detection Operations Center. Emerg. Health Threats J. 6, 20632 (2013).
4. S. G. Franzblau, M. A. DeGroote, S. H. Cho, K. Andries, E. Nuermberger, I. M. Orme, K. Mdluli, I. Angulo-Barturen, T. Dick, V. Dartois, A. J. Lenaerts, Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis 92, 453-488 (2012).
5. V. Dartois, C. E. Barry III, A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg. Med. Chem. Lett. 23, 4741-4750 (2013).
6. D. A. Mitchison, K. C. Chang, Experimental models of tuberculosis: Can we trust the mouse? Am. J. Respir. Crit. Care Med. 180, 201-202 (2009).
7. A. R. Coates, Y. Hu, A. Jindani, D. A. Mitchison, Contradictory results with high-dosage rifamycin in mice and humans. Antimicrob. Agents Chemother. 57, 1103 (2013).
8. L. E. Via, P. L. Lin, S. M. Ray, J. Carrillo, S. S. Allen, S. Y. Eum, K. Taylor, E. Klein, U. Manjunatha, J. Gonzales, E. G. Lee, S. K. Park, J. A. Raleigh, S. N. Cho, D. N. McMurray, J. L. Flynn, C. E. Barry III, Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun. 76, 2333-2340 (2008).
9. S. Y. Eum, J. H. Kong, M. S. Hong, Y. J. Lee, J. H. Kim, S. H. Hwang, S. N. Cho, L. E. Via, C. E. Barry III, Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137, 122-128 (2010).
10. M. Lee, J. Lee, M. W. Carroll, H. Choi, S. Min, T. Song, L. E. Via, L. C. Goldfeder, E. Kang, B. Jin, H. Park, H. Kwak, H. Kim, H. S. Jeon, I. Jeong, J. S. Joh, R. Y. Chen, K. N. Olivier, P. A. Shaw, D. Follmann, S. D. Song, J. K. Lee, D. Lee, C. T. Kim, V. Dartois, S. K. Park, S. N. Cho, C. E. Barry III, Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 367, 1508-1518 (2012).
11. J. A. Ippolito, Z. F. Kanyo, D. Wang, F. J. Franceschi, P. B. Moore, T. A. Steitz, E. M. Duffy, Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med. Chem. 51, 3353-3356 (2008).
12. A. E. Barnhill, M. T. Brewer, S. A. Carlson, Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components. Antimicrob. Agents Chemother. 56, 4046-4051 (2012).
13. K. E. Dooley, E. L. Nuermberger, A. H. Diacon, Pipeline of drugs for related diseases: Tuberculosis. Curr. Opin. HIV AIDS 8, 579-585 (2013).
14. O. Urbina, O. Ferrández, M. Espona, E. Salas, I. Ferrández, S. Grau, Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections. Drug Des. Devel. Ther. 7, 243-265 (2013).
15. V. Balasubramanian, S. Solapure, H. Iyer, A. Ghosh, S. Sharma, P. Kaur, R. Deepthi, V. Subbulakshmi, V. Ramya, V. Ramachandran, M. Balganesh, L. Wright, D. Melnick, S. L. Butler, V. K. Sambandamurthy, Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob. Agents Chemother. 58, 495-502 (2014).
16. A. Wookey, P. J. Turner, J. M. Greenhalgh, M. Eastwood, J. Clarke, C. Sefton, AZD2563, a novel oxazolidinone: Definition of antibacterial spectrum, assessment of bactericidal potential and the impact ofmiscellaneous factors on activity in vitro. Clin.Microbiol. Infect. 10, 247-254 (2004).
17. P. L. Lin, V. Dartois, P. J. Johnston, C. Janssen, L. Via, M. B. Goodwin, E. Klein, C. E. Barry III, J. L. Flynn, Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc. Natl. Acad. Sci. U.S.A. 109, 14188-14193 (2012).
18. P. L. Lin, T. Coleman, J. P. Carney, B. J. Lopresti, J. Tomko, D. Fillmore, V. Dartois, C. Scanga, L. J. Frye, C. Janssen, E. Klein, C. E. Barry III, J. L. Flynn, Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob. Agents Chemother. 57, 4237-4244 (2013).
19. L. E. Via, D. M. Weiner, D. Schimel, P. L. Lin, E. Dayao, S. L. Tankersley, Y. Cai, M. T. Coleman, J. Tomko, P. Paripati, M. Orandle, R. J. Kastenmayer, M. Tartakovsky, A. Rosenthal, D. Portevin, S. Y. Eum, S. Lahouar, S. Gagneux, D. B. Young, J. L. Flynn, C. E. Barry III, Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus ). Infect. Immun. 81, 2909-2919 (2013).
20. P. L. Lin, S. Pawar, A. Myers, A. Pegu, C. Fuhrman, T. A. Reinhart, S. V. Capuano, E. Klein, J. L. Flynn, Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect. Immun. 74, 3790-3803 (2006).
21. P. L. Lin, M. Rodgers, L. Smith, M. Bigbee, A. Myers, C. Bigbee, I. Chiosea, S. V. Capuano, C. Fuhrman, E. Klein, J. L. Flynn, Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect. Immun. 77, 4631-4642 (2009).
22. B. McGee, R. Dietze, D. J. Hadad, L. P. Molino, E. L. Maciel, W. H. Boom, M. Palaci, J. L. Johnson, C. A. Peloquin, Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob. Agents Chemother. 53, 3981-3984 (2009).
23. S. Reele, A. J. Xiao, S. Das, V. Balasubramanian, D. Melnick, papers (A1-1734 and A1-1735) presented at the 51st ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 17 to 20 September 2011.
24. P. L. Lin, C. B. Ford, M. T. Coleman, A. J. Myers, R. Gawande, T. Ioerger, J. Sacchettini, S. M. Fortune, J. L. Flynn, Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat. Med. 20, 75-79 (2014).
25. R. Y. Chen, L. E. Dodd, M. Lee, P. Paripati, D. A. Hammoud, J. M. Mountz, D. Jeon, N. Zia, H. Zahiri, M. T. Coleman, M. W. Carroll, J. D. Lee, Y. J. Jeong, P. Herscovitch, S. Lahouar, M. Tartakovsky, A. Rosenthal, S. Somaiyya, S. Lee, L. C. Goldfeder, Y. Cai, L. E. Via, S. K. Park, S. N. Cho, C. E. Barry III, PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci. Transl. Med. 6, 265ra166 (2014).
26. A. Tse-Chang, D. Kunimoto, E. Der, R. Ahmed, Assessment of linezolid efficacy, safety and tolerability in the treatment of tuberculosis: A retrospective case review. Can. J. Infect. Dis. Med. Microbiol. 24, e50-e52 (2013).
27. C. Roongruangpitayakul, C. Chuchottaworn, Outcomes of MDR/XDR-TB patients treated with linezolid: Experience in Thailand. J. Med. Assoc. Thai. 96, 1273-1282 (2013).
28. G. Sotgiu, R. Centis, L. D'Ambrosio, A. Spanevello, G. B. Migliori; International Group for the study of Linezolid, Linezolid to treat extensively drug-resistant TB: Retrospective data are confirmed by experimental evidence. Eur. Respir. J. 42, 288-290 (2013).
29. K. C. Chang, W. W. Yew, S. W. Cheung, C. C. Leung, C. M. Tam, C. H. Chau, P. K. Wen, R. C. Chan, Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? Antimicrob. Agents Chemother. 57, 3445-3449 (2013).
30. J. E. de Steenwinkel, G. J. de Knegt, M. T. ten Kate, A. van Belkum, H. A. Verbrugh, K. Kremer, D. van Soolingen, I. A. Bakker-Woudenberg, Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 65, 2582-2589 (2010).
31. C. E. Barry III, H. I. Boshoff, V. Dartois, T. Dick, S. Ehrt, J. Flynn, D. Schnappinger, R. J. Wilkinson, D. Young, The spectrum of latent tuberculosis: Rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7, 845-855 (2009).
32. B. Efron, R. Tibshirani, An Introduction to the Bootstrap (Chapman & Hall/CRC, Boca Raton, FL, 1993).